February 18, 2025--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq ... only previously available to family members for trio testing and for all exome testing. Added content: expanded the number ...

February 18, 2025--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq ... Buccal samples for WGS were only previously available to family members for trio testing and for all exome testing. Added content: ...

GAITHERSBURG, Md., March 04, 2025--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, announced today an indication expansion for its ...

GeneDx excels in comprehensive genome and exome testing using a vast genetic database linking 400+ diseases. The company cuts diagnostic times from years to days, enhancing patient outcomes and ...

Through the combination of GeneDx’s industry leading proprietary dataset, publicly available data, and the power of AI, Multiscore prioritizes genes with positive findings in exome and genome ...

This strategic indication expansion underscores the importance of improving access to exome and genome testing for patients with CP to shorten the diagnostic odyssey and accelerate the path to ...

GeneDx Holdings Corp. is delivering strong revenue growth, but it is still burning cash. Click here for more on WGS stock ...

GeneDx’s industry leading exome and genome empower clinicians with comprehensive genetic insights to uncover genetic factors contributing to CP. The testing provides valuable information that ...

Through the combination of GeneDx’s industry leading proprietary dataset, publicly available data, and the power of AI, Multiscore prioritizes genes in exome and genome sequences by ranking them ...

Multiscore, a Gene Ranker Powered by Artificial Intelligence and Real-World Clinical Data, Shows High Sensitivity in 10,000 Exomes and Genomes will be presented by Vinnie Ustach, PhD (GeneDx) on ...

2024 was a remarkable year for GeneDx across all metrics. We cemented and extended our position as the market leader in the exome and genome testing, expanded patient access, solidified our ...